4-Chloro-2-hydroxybenzenesulfonamide | 1243372-63-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Chloro-2-hydroxybenzenesulfonamide
• CAS: 1243372-63-5
• 化学式: C₆H₆ClNO₃S
• mdl: MFCD16999674
• 分子量: 207.64
• InChiKey: BBVYHVGLQROERW-UHFFFAOYSA-N

物化性质

• 沸点：
  391.5±52.0 °C(Predicted)
• 密度：
  1.612±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANORECTAL DISORDERS
  申请人：Cellegy Pharmaceuticals, Inc

  公开号：EP1315499A1

  公开（公告）日：2003-06-04
• EP1315499A4
  申请人：——

  公开号：EP1315499A4

  公开（公告）日：2007-09-05
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANORECTAL DISORDERS<br/>[FR] COMPOSITIONS ET METHODES DESTINEES AU TRAITEMENT DES TROUBLES ANORECTAUX
  申请人：CELLEGY PHARMA INC

  公开号：WO2002009714A1

  公开（公告）日：2002-02-07

  Compositions and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2-) scavengers, β-adrenergic agonists, cAMP-dependent protein kinase activators, α¿1?-adrenergic antagonists, L-type Ca?2+¿ channel blockers, estrogens, ATP-sensitive + channel activators and smooth muscle relaxants are used.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANORECTAL DISORDERS<br/>[FR] COMPOSITIONS ET METHODES DE TRAITEMENT DE TROUBLES ANO-RECTAUX
  申请人：CELLEGY PHARMA INC

  公开号：WO2003075851A2

  公开（公告）日：2003-09-18

  Compositions and methods for the treatment of patients with anorectal disorders including colostomy are provided in which certain compounds including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators (including acetylcholine storage blocking agents and acetylcholine vesicle storage blocking agents), α-adrenergic receptor antagonists (including α1-adrenergic antagonists and α2-adrenergic antagonists), β-adrenergic receptor agonists (including β2-adrenergic antagonists and β3-adrenergic antagonists), phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g., cAMP mimetics), superoxide scavengers, potassium channel activators (including ATP-sensitive potassium channel activators and activators of the Maxi-K channels), estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators, endothelin receptor antagonists, bisphosphonates, cGMP-dependent protein kinase activators (e.g., cGMP mimetics), and combinations thereof are used.
• [EN] THERAPEUTIC AND PROGNOSTIC FACTOR YY1 IN HUMAN CANCER<br/>[FR] FACTEUR THERAPEUTIQUE ET PRONOSTIQUE YY1 DANS LE CANCER HUMAIN
  申请人：UNIV CALIFORNIA

  公开号：WO2007011372A2

  公开（公告）日：2007-01-25

  [EN] The present invention provides for the first time YY1, a transcription factor gene over-expressed and/or functionally overactive in human cancer. The present invention provides methods of diagnosing and providing a prognosis for cancer such as prostate cancer, as well as methods of drug discovery. YY1 is also a therapeutic target for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition of YY1 expression and/or activity sensitizes resistant tumor cells to cytotoxic treatments, including chemotherapy, radiation therapy, hormonal therapy, and immunotherapy.
  [FR] L'invention concerne YY1 qui est un gène de facteur de transcription surexprimé et/ou suractif dans le cancer humain. L'invention concerne des méthodes de diagnostic et de pronostic du cancer, tel que le cancer de la prostate, ainsi que des méthodes de découverte de médicaments. YY1 est également une cible thérapeutique permettant de traiter un cancer résistant aux thérapeutiques classiques et expérimentales du cancer. L'inhibition de l'expression et/ou de l'activité de YY1 sensibilise des cellules tumorales résistant à des traitements cytotoxiques, notamment, la chimiothérapie, la radiothérapie, la thérapie hormonale et l'immunothérapie.